Towards An Etiological Understanding Of The Comorbidity Of Psychiatric Disorders
Funder
National Health and Medical Research Council
Funding Amount
$997,883.00
Summary
Pyschiatric disorders are common disorders with both genetic and environmental etilogy. The disorders are characterised both by significant overlap of symptoms and by significant heterogenity of symptoms within disorders. The availability of genome-wide genotypes allows us, for the first time, to investigate co-morbidity directly at the molecular level. Understanding the nature of co-morbidity between disorders nay be an important key to effective treatment.
Overcoming Barriers To Improved Physical Health In People With Severe Mental Illness
Funder
National Health and Medical Research Council
Funding Amount
$864,658.00
Summary
People with severe mental illness have high rates of cardiometabolic disease and reduced life-expectancy. Public intervention campaigns have had little impact on component risks (obesity, smoking, physical inactivity, poor nutrition). This study will determine factors associated with changes in cardiometabolic profiles in people with severe mental illness; examine impediments to risk modification; and develop targeted interventions for implementation within mental health services.
Roles Of Muscarinic M3 Receptors In Antipsychotic-induced Metabolic Side-effects: Prevention And Treatment Of Antipsychotic-induced Insulin Dysregulation
Funder
National Health and Medical Research Council
Funding Amount
$603,825.00
Summary
Antipsychotic drugs are used to treat various mental disorders, such as schizophrenia, bipolar disorder, dementia and major depression. However, these drugs cause serious metabolic side-effects leading to premature death and huge costs to the Australian health care system. This project aims to reveal the role of muscarinic M3 receptors in antipsychotic-induced insulin dysregulation that precedes diabetes. Understanding these mechanisms will provide new strategies for the prevention and treatment ....Antipsychotic drugs are used to treat various mental disorders, such as schizophrenia, bipolar disorder, dementia and major depression. However, these drugs cause serious metabolic side-effects leading to premature death and huge costs to the Australian health care system. This project aims to reveal the role of muscarinic M3 receptors in antipsychotic-induced insulin dysregulation that precedes diabetes. Understanding these mechanisms will provide new strategies for the prevention and treatment of these critical adverse effects.Read moreRead less
Improving Physical Health Outcomes For Young People With Psychotic Disorders
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Enduring psychotic disorders are associated with a reduced life expectancy by 25 years, which is mainly due to cardiovascular disease. This project will produce a training package that will improve clinician’s skills and knowledge of screening and treatment for physical health risk factors in young people with psychosis. This project will result in the development of an intervention for reducing the prevalence of these cardiovascular risk factors known to contribute to this early mortality.
Cardiometabolic Health Of People With Severe And Persistent Mental Illness
Funder
National Health and Medical Research Council
Funding Amount
$187,322.00
Summary
People with schizophrenia have much higher rates of smoking, obesity and diabetes. To date, psycho-social interventions to reduce these physical health risk factors have had limited success. This research aims to conduct clinical trials among people with schizophrenia of 1. a novel diabetes medication to help people lose weight and gain better control of their sugars, and 2. newly developed vaporised nicotine products to help reduce cigarette smoking.